Findings

What do systematic reviews say?

3,696 questions · 3,815 findings · 855 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 573 · 15%GRADE not reported 374 · 9.8%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Topical antimicrobial agent vs topical non‐antimicrobial agent

Time to complete healing

1 finding from 1 review

Topical treatment for facial burns 2020 · Cochrane Headline outcomes only
no estimate extracted
60 participants
Low

Topical antimicrobial agent vs topical non‐antimicrobial agent

Proportion of wounds healed

Topical antimicrobial agent showed no clear difference in proportion of wounds completely healed within 10 days (10 days) compared with topical non‐antimicrobial agent (low certainty).

1 finding from 1 review

Topical treatment for facial burns 2020 · Cochrane Headline outcomes only
RR 0.94 [0.68, 1.29]
39 participants
Low

Summary of findings: ECM vs ECT

Abdominal pain frequency or change in frequency · adults and children with cystic fibrosis

It is very uncertain whether summary of findings: ECM changes frequency of bowel symptoms: abdominal pain (% of days affected) compared with ECT (very low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 41 participants
Very low

Summary of findings: ECM vs ECT

CFA: change in FFE (g/day) · adults and children with cystic fibrosis

Summary of findings: ECM showed no clear difference in CFA: change in FFE (g/day) compared with ECT (low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 41 participants
Low

Summary of findings: ECM vs ECMM

CFA: change in FFE (g/day) · children with cystic fibrosis and proven pancreatic insufficiency

It is very uncertain whether summary of findings: ECM changes CFA: change in FFE (g/day) compared with ECMM (very low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings: ECM vs a different ECM

Abdominal pain frequency or change in frequency · adults and children with cystic fibrosis

Summary of findings: ECM (Creon®) showed no clear difference in frequency of bowel symptoms: proportion of days with abdominal pain compared with a different ECM (low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
MD 0
1 study · 83 participants
Low

Summary of findings: ECM vs TPE

CFA: change in FFE (g/day) · children with cystic fibrosis

It is very uncertain whether summary of findings: ECM changes CFA: change in FFE (g/day) compared with TPE (very low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Summary of findings: ECM vs NECT plus cimetidine

Abdominal pain frequency or change in frequency · adults with cystic fibrosis

It is very uncertain whether summary of findings: ECM changes frequency in bowel symptoms: abdominal pain (% of days affected) compared with NECT plus cimetidine (very low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Summary of findings: low‐dose vs high‐dose PERT

CFA: FFE (g/day) · adults and children with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Summary of findings: ECM vs NECT plus cimetidine

CFA: change in FFE (g/day) · adults with cystic fibrosis

Summary of findings: ECM showed no clear difference in CFA: change in FFE (g/day) compared with NECT plus cimetidine (low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Corticosteroids vs placebo

Days missed from work or school · patients with sore throat

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 405 participants
Moderate

Brain‐derived neurotrophic factor vs placebo

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Cerebrospinal fluid filtration vs plasma exchange

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Very low

Interferon beta‐1a vs placebo

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Intervention not reported

Treatment failure day‐28 PCR‐adjusted(PP population) · children aged 14 years or younger with uncomplicated P falciparum malaria

The intervention showed no clear difference in treatment failure day‐28 PCR‐adjusted(PP population) (low certainty).

1 finding from 1 review

Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children 2020 · Cochrane Headline outcomes only
RR 1.35 [0.49, 3.72]
2 studies · 1061 participants
Low

Intervention not reported

Treatment failureday‐28 PCR‐adjusted(ITT population) · children aged 14 years or younger with uncomplicated P falciparum malaria

The intervention showed no clear difference in treatment failureday‐28 PCR‐adjusted(ITT population) (low certainty).

1 finding from 1 review

Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children 2020 · Cochrane Headline outcomes only
RR 1.05 [0.68, 1.62]
2 studies · 1139 participants
Low

Levosimendan vs dobutamine

All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.6 [0.36, 1.03]
4 studies · 1701 participants
Low

Epinephrine vs norepinephrine

All‐cause short‐term mortality: 28 daysÂ · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 daysÂ compared with norepinephrine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.81 [0.89, 3.68]
1 study · 57 participants
Very low

Epinephrine vs norepinephrine

All‐cause long‐term mortality: 60 days · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.41 [0.78, 2.56]
1 study · 57 participants
Very low

Levosimendan vs enoximone

All‐cause short‐term mortality: 30 days · adults with cardiogenic shock

It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.5 [0.22, 1.14]
1 study · 32 participants
Very low